Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
No one on the platform currently holds IRAA.
No tracked institution reports a position in IRAA as of their last filing.
No one on the platform has traded IRAA yet.
No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.
$IRAA Liminatus Pharma ($LIMN) just dropped a brand-new investor intro video and barely anyone's watching yet. They're developing cutting-edge immunotherapies targeting Claudin18.2+ solid tumors, an emerging biomarker that's already drawn billion-dollar deals from major pharma players like Astellas. What makes LIMN stand out? A low float, a clean SPAC merger, and a pipeline backed by the NIH — this isn’t your average penny biotech. Why this matters: Claudin18.2 is a red-hot target in gastric & pancreatic cancers NIH collaboration gives them serious scientific credibility Trading under the radar with minimal volume = early entry potential Low float + catalyst = possible sharp upside Check out their intro video (uploaded just yesterday): 📽️ https://www.youtube.com/watch?v=36NnT_HNtl0 And pipeline breakdown: 🔗 http://liminatuspharma.com/bbs/content.php?co_id=cancer I’m waiting for a move when volume picks up.
View on StockTwits ↗$IRAA changed tickers to ($LIMN) Liminatus Pharma ($LIMN) just dropped a brand-new investor intro video and barely anyone's watching yet. They're developing cutting-edge immunotherapies targeting Claudin18.2+ solid tumors, an emerging biomarker that's already drawn billion-dollar deals from major pharma players like Astellas. What makes LIMN stand out? A low float, a clean SPAC merger, and a pipeline backed by the NIH — this isn’t your average penny biotech. Why this matters: Claudin18.2 is a red-hot target in gastric & pancreatic cancers. NIH collaboration gives them serious scientific credibility. Trading under the radar with minimal volume = early entry potential. Low float + catalyst = possible sharp upside. Check out their intro video: 📽️ https://www.youtube.com/watch?v=36NnT_HNtl0 And pipeline breakdown: 🔗 http://liminatuspharma.com/bbs/content.php?co_id=cancer I’m watching for a move when volume picks up again. $TSLA $GME $SPY $BTC
View on StockTwits ↗$IRAA Volume brings massive swings here $BTC $TRUMP.X $DOGE.X
View on StockTwits ↗$IRAA changed ticker to $LIMN The free float for LIMN (Liminatus Pharma Inc.) is 174.48K shares. This means that out of the total 7.07M shares outstanding, only 174.48K are available for public trading. The remaining shares are likely held by insiders, promoters, or other restricted parties. A smaller free float can sometimes lead to higher price volatility, as fewer shares are available for trading, Already spiked 5 to 24 / 8 to 16 just fyi do whatever you wanna do. $TSLA $GME
View on StockTwits ↗$IRAA wish I could add more, I'm all in already waiting for takeoff!
View on StockTwits ↗$IRAA $LIMN just a matter of time here. This can turn into a halt monster at any moment consider yourself lucky if you can load these cheapies
View on StockTwits ↗$IRAA look at RGC and NTCL That will be us. Whether it takes a day or a week or a month, it’s going to happen.
View on StockTwits ↗$IRAA Goos morning @Stocktwits ... you would offer me paid services and even the ability to trade on your platform, yet you cannot update a ticker change after four trading days? I don't know if I want to throw my money down on an app who cannot keep current within at least one trading day. Guess I'll stick with RH.
View on StockTwits ↗@Stocktwits I'd like to send you a direct message, please follow me so we can chat please change ticker symbol $IRAA
View on StockTwits ↗$IRAA so I see 7 million shares total and only 170k float. Anyone know when the other 6.8 million shares enter the float
View on StockTwits ↗$IRAA Yes, ticker change please! @StocktwitsSupportChannel @Stocktwits
View on StockTwits ↗Recent $TICKER stream from stocktwits.com — refreshed every 5 minutes. Sentiment tags are self-reported by posters. Not investment advice.